0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      MIF mediates bladder pain, not inflammation, in cyclophosphamide cystitis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          • MIF mediates bladder pain but not bladder inflammation induced by CYP.

          • ISO-1 blocks CYP induced bladder inflammation independent of MIF.

          • MIF may mediate bladder pain by promoting bladder ERK phosphorylation.

          Abstract

          Macrophage migration inhibitory factor (MIF), a proinflammatory mediator, is recognized as a player in inflammatory and neuropathic pain. Cyclophosphamide (CYP) results in bladder inflammation and pain and it’s a frequently used animal model of interstitial cystitis/bladder pain syndrome (IC/BPS). Because pretreatment with a MIF inhibitor (ISO-1) prevented both CYP-induced bladder pain and inflammation we used genetic MIF knockout (KO) mice to further investigate MIF’s role in CYP-induced bladder pain and inflammation. Abdominal mechanical threshold measured bladder pain induced by CYP in wild type (WT) and MIF KO mice at several time points (0–48 h). End-point (48 h) changes in micturition parameters and histological signs of bladder inflammation were also evaluated. Abdominal mechanical hypersensitivity developed within 4 h after CYP injection (and lasted for the entire observation period: 48 h) in WT mice. MIF KO mice, on the other hand, did not develop abdominal mechanical hypersensitivity suggesting that MIF is a pivotal molecule in mediating CYP-induced bladder pain. Both WT and MIF KO mice treated with CYP showed histological signs of marked bladder inflammation and showed a significant decrease in micturition volume and increase in frequency. Since both changes were blocked in MIF KO mice by pretreatment with a MIF inhibitor (ISO-1) it is likely these are non-specific effects of ISO-1. MIF mediates CYP-induced bladder pain but not CYP-induced bladder inflammation. The locus of effect (bladder) or central (spinal) for MIF mediation of bladder pain remains to be determined.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: not found
          • Article: not found

          Efficient analysis of experimental observations.

          W. Dixon (1980)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Quantitative assessment of tactile allodynia in the rat paw.

            We applied and validated a quantitative allodynia assessment technique, using a recently developed rat surgical neuropathy model wherein nocifensive behaviors are evoked by light touch to the paw. Employing von Frey hairs from 0.41 to 15.1 g, we first characterized the percent response at each stimulus intensity. A smooth log-linear relationship was observed, with a median 50% threshold at 1.97 g (95% confidence limits, 1.12-3.57 g). Subsequently, we applied a paradigm using stimulus oscillation around the response threshold, which allowed more rapid, efficient measurements. Median 50% threshold by this up-down method was 2.4 g (1.81-2.76). Correlation coefficient between the two methods was 0.91. In neuropathic rats, good intra- and inter-observer reproducibility was found for the up-down paradigm; some variability was seen in normal rats, attributable to extensive testing. Thresholds in a sizable group of neuropathic rats showed insignificant variability over 20 days. After 50 days, 61% still met strict neuropathy criteria, using survival analysis. Threshold measurement using the up-down paradigm, in combination with the neuropathic pain model, represents a powerful tool for analyzing the effects of manipulations of the neuropathic pain state.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Macrophage migration inhibitory factor (MIF): a promising biomarker.

              Macrophage migration inhibitory factor (MIF) is an immunoregulatory cytokine, the effect of which on arresting random immune cell movement was recognized several decades ago. Despite its historic name, MIF also has a direct chemokine-like function and promotes cell recruitment. Multiple clinical studies have indicated the utility of MIF as a biomarker for different diseases that have an inflammatory component; these include systemic infections and sepsis, autoimmune diseases, cancer, and metabolic disorders such as type 2 diabetes and obesity. The identification of functional promoter polymorphisms in the MIF gene (MIF) and their association with the susceptibility or severity of different diseases has not only served to validate MIF's role in disease development but also opened the possibility of using MIF genotype information to better predict risk and outcome. In this article, we review the clinical data of MIF and discuss its potential as a biomarker for different disease applications. Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                Cytokine X
                Cytokine X
                Cytokine
                Elsevier
                2590-1532
                23 January 2019
                March 2019
                23 January 2019
                : 1
                : 1
                : 100003
                Affiliations
                [a ]Research and Development, Lexington Veterans Affairs Health Care System, Lexington, KY, United States
                [b ]Department of Physiology, University of Kentucky, Lexington, KY, United States
                [c ]Department of Natural Sciences, St. Petersburg College, St. Petersburg, FL, United States
                [d ]Department of Internal Medicine, Yale University, New Haven, CT, United States
                [e ]Department of Surgery, University of Kentucky, Lexington, KY, United States
                Author notes
                [* ]Corresponding author at: Lexington Veteran Health Care System, 1101 Veterans Drive, Room C-332, Lexington, KY 40502, United States. Pedro.Vera@ 123456va.gov
                [1]

                Current Address: Department of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Maywood, IL, United States.

                Article
                S2590-1532(19)30002-3 100003
                10.1016/j.cytox.2019.100003
                6615480
                31289792
                371963f0-1c62-4550-83a7-97b2c6f50e64
                © 2019 Published by Elsevier Ltd.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Research Article

                mif, macrophage migration inhibitory factor,cyp, cyclophosphamide,ko, knockout,wt, wild type,erk, extracellular signal regulated kinases 1/2,ic/bps, interstitial cystitis/bladder pain syndrome,mif,cyp,iso-1,bladder pain,erk

                Comments

                Comment on this article